Commentary

Joseph A. DiMasi
Additional contact information
Joseph A. DiMasi: Tufts Center for the Study of Drug Development, Tufts University, USA, Postal: Tufts Center for the Study of Drug Development, Tufts University, USA

Managerial and Decision Economics, 2007, vol. 28, issue 4-5, pages 285-291

Abstract: The three papers by Scherer (2007), Berndt et al. (2007), and Reiffen and Ward (2007) in this issue cover disparate topics, but together they manage to encompass much of what is important during a drug's lifecycle. Scherer's paper examines pharmaceutical industry R&D productivity and efficacy and safety testing during a new drug's development, Berndt, Danzon and Kruse investigate cross-national data on utilization, pricing, promotion, and diffusion of brand name drugs after they have been developed for marketing approval, and Reiffen and Ward explore generic competition once a new drug loses patent protection. They add much to our understanding of these topics. Copyright © 2007 John Wiley & Sons, Ltd.

Date: 2007
View list of references

Downloads: (external link)
http://hdl.handle.net/10.1002/mde.1341 Link to full text; subscription required (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: http://EconPapers.repec.org/RePEc:wly:mgtdec:v:28:y:2007:i:4-5:p:285-291

Access Statistics for this article

Managerial and Decision Economics is edited by Paul H. Rubin

More articles in Managerial and Decision Economics from John Wiley & Sons, Ltd.
Series data maintained by Christopher F. Baum ().